ALK Fusion

CI-VAR-00001159Explore in graph →CIViC 5

Curated evidence

Evidence by cancer (118 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 101–118 of 118 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm14
EML4::ALK Fusion AND ALK L1198F	Crizotinib	Predictive	D	Supports Sensitivity Response	4	submitted	EID7603 The EML4-ALK fusion resistance mutation L1198F was shown to increase sensitivity of cells to crizotinib in vitro. In cell survival assays Ba/F3 cells expressing L1198F mutated EML4-ALK had even greate… (full text at CIViC) PMID 26698910 · Shaw et al., 2016 · Open in CIViC	civic
EML4::ALK Fusion AND ALK L1198F AND ALK C1156Y	Crizotinib	Predictive	D	Supports Sensitivity Response	4	submitted	EID7605 The EML4-ALK fusion compound resistance mutation C1156Y-L1198F was shown to re-sensitize cells to crizotinib in vitro. In cell survival assays Ba/F3 cells expressing C1156Y-L1198F mutated EML4-ALK wer… (full text at CIViC) PMID 26698910 · Shaw et al., 2016 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Pleural Malignant Mesothelioma4
EML4::ALK Fusion	Alectinib	Predictive	C	Supports Sensitivity Response	4	accepted	EID9228 A 33 year old M non-smoker with no cancer family history and no known exposure to asbestos showed weakness, chest pain, and plural effusion (PE) accumulation. Mass in right lung was seen under enhance… (full text at CIViC) PMID 32600123 · Hu et al., 2020 · Open in CIViC	civic
EML4::ALK Fusion AND ALK G1202R AND ALK I1171N AND ALK L1196M	Lorlatinib	Predictive	C	Supports Resistance	3	accepted	EID11114 This case report describes a 33 year-old non-smoker with no known exposure to asbestos who was diagnosed with stage IIIB malignant pleural mesothelioma. Panel next generation sequencing (NGS) of 520 g… (full text at CIViC) PMID 32600123 · Hu et al., 2020 · Open in CIViC	civic
EML4::ALK Fusion AND ALK I1171N AND ALK L1196M	Alectinib	Predictive	C	Supports Resistance	4	accepted	EID11115 A 33 year old male with no smoking history or known exposure to asbestos was diagnosed with malignant pleural mesothelioma (MPM). EML4::ALK was found using a panel of 520 genes in NGS, and the patient… (full text at CIViC) PMID 32600123 · Hu et al., 2020 · Open in CIViC	civic
EML4::ALK Fusion AND ALK I1171N AND ALK L1196M	Lorlatinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID11113 This case report describes a 33 year-old non-smoker with no known exposure to asbestos who was diagnosed with stage IIIB malignant pleural mesothelioma. Panel next generation sequencing (NGS) of 520 g… (full text at CIViC) PMID 32600123 · Hu et al., 2020 · Open in CIViC	civic